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Expression analysis of a novel cDNA isolated from
immortal murine fibroblasts revealed a single tran-
script of 3.0 kilobase pairs that was highly expressed in
mouse and human striated muscle and in mouse heart.
The gene has therefore been named striamin. Its expres-
sion was confined to skeletal muscle types with a fast
glycolytic (2B) contractile phenotype. It was also de-
tected in C2C12 mouse myoblasts and was down-regu-
lated during in vitro myogenesis. The cDNA has a single
open reading frame encoding a predicted 16.8-kDa pro-
tein of 149 amino acids with no homology to known
proteins. Microinjection and transfection of green fluo-
rescence protein-tagged striamin demonstrated that it
localizes to the nucleus. Coimmunoprecipitations re-
vealed that it can interact with p53 (a positive marker
for myoblast differentiation) in vivo and in vitro. Fur-
thermore, it repressed p53 activity in p53-mediated re-
porter assays. Fluorescence in situ hybridization with a
mouse P1 genomic clone localized the gene to chromo-
some 12C3, which is syntenic to human chromosome
14q21–22.
Several genes, such as muscle creatine kinase, troponins,
caveolin-3, a-actin, and myosin, have been reported to be pre-
dominantly expressed in skeletal muscle. A family of muscle-
specific transcription factors such as myoD, myogenin, myf-5,
and MRF-4/herculin/myf-6 that regulate muscle-specific gene
expression has also been cloned. These are phosphorylated
nuclear proteins, containing helix-loop-helix motifs required
for dimerization and DNA binding, that can determine a spe-
cific cellular differentiation program (1). The myoD family of
transcription factors has been shown to direct myogenesis,
repress proliferation, activate differentiation, and induce con-
tractile phenotypes. The introduction of any one of these into
nonmyogenic cells induces their differentiation into mature
muscle cells (2). The MyoD and myf-5 are expressed in prolif-
erating myoblasts whereas myogenin and MRF-4 are not ex-
pressed until myoblasts exit the cell cycle in response to mito-
gen depletion. Therefore, myoD and myf-5 have been im-
plicated as having a role in proliferating myoblasts whereas
myogenin and MRF-4 have been shown to activate and main-
tain muscle gene expression (3). In addition, the cell cycle
regulatory proteins such as RB (4, 5), p21 (6), cyclin D, cdk2,
cdk4 (7), and p53 (8) have been implicated in the muscle dif-
ferentiation program. Recently, caveolin-3, a-dystroglycan, and
DNA methyltransferase (9–11) have also been assigned a pos-
itive role in myogenic differentiation.
While looking for genes involved in senescence and immor-
talization, we fortuitously cloned a novel gene that is specifi-
cally expressed in fast twitch skeletal muscles. The gene is
named “striamin” because of its specific expression in striated
muscle. Cloning of the cDNA, expression analyses, subcellular
localization, chromosomal assignment, its interactions with the
tumor suppressor p53, and its possible significance during
muscle differentiation are reported herein.
EXPERIMENTAL PROCEDURES
Cell Culture—Normal mouse embryonic fibroblasts from the CD1-
ICR strain of mouse (CMEF), an immortal clone (RS-4) established from
CMEF, and NIH 3T3 cells, initially used for comparison of proteins and
cloning studies, were cultured as described (12). C2 cells originally
isolated by Yaffe and Saxel (13) and subcloned by Blau et al. (14) were
grown in DMEM (Life Technologies, Inc., Melbourne, Australia) sup-
plemented with 20% FCS (Commonwealth Serum Labs, Melbourne,
Australia) and 0.5% chick embryo extract (Flow Laboratories, North
Ryde, Australia). Cells were induced to differentiate by replacing
growth medium with mitogen-poor medium, DMEM plus 2% horse
serum. COS7 and Rat-1 cells used for transfection and microinjection
studies were cultured in DMEM supplemented with 10% FCS.
cDNA Cloning and Sequencing—A cDNA library from RS-4 cells was
constructed in the lZAP II vector and was screened with a polyclonal
anti-p33 antibody raised against a protein identified from P-100 frac-
tions of NIH 3T3 cells (12). cDNA clones were sequenced by the dideoxy
chain termination method, and the reactions were analyzed on an ABI
377 automated sequencing machine. Full sequence of a 2.4-kb cDNA
clone designated 336 was derived by generation of nested deletions from
the 39 end by exonuclease III (Deletion kit, Takara, Tokyo, Japan) and
primer walking. Subsequently, the 59 end of the cDNA was obtained by
59 Marathon™ RACE polymerase chain reaction (PCR) on mouse skel-
etal muscle cDNA by using three antisense gene-specific primers SP1
(59-TGT CAC TGC CAC GCC TTC TCG GTG CGC AG -39), SP2 (59-TCC
CGG CTG CCC TTT GGC CCA TCT TGT CCC -39) and SP3 (59-TGA
GAA AGC GTT AGA CGC TCT CAG AGC CCT-39). 59 Marathon™
RACE PCR was performed as described (CLONTECH).
RNA Isolation—Total RNA was prepared from C2C12 cultures
grown in DMEM supplemented with 20% FCS or 2% horse serum
(differentiation medium, for 24–96 h) using Trizol (Life Technologies,
Inc). Skeletal muscles were excised from B6D2 males (F1 progeny of
C57BL/6J female 3 DBA/2J male matings), frozen in liquid N2, and
homogenized in denaturant. Total cellular RNA was isolated from all
muscle samples using the Trizol reagent.
Northern Blot and RT-PCR Analyses—Mouse and human multiple
tissue Northern blots containing 2 mg of poly(A)1 RNA per lane were
purchased from CLONTECH. Total cellular RNA from C2C12 cultures
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and B6D2 muscles was denatured and size fractionated on 1% agarose
gels containing 2.2 M formaldehyde and transferred to Hybond N mem-
brane (Amersham Pharmacia Biotech). A 1.4-kb 39-untranslated region
fragment obtained by BamHI digestion of pBSSK-336 plasmid was used
as a probe. Hybridization was performed at 65 °C in SSC-Denhardt’s-
SDS buffer. The membrane was washed for 10 min each in 23 SSC, 23
SSC and 0.1% SDS, then washed in 13 SSC and 0.1% SDS twice, and
autoradiographed. RNA loading on the blots was determined by hybrid-
ization with 18 S ribosomal probe. RT-PCR was performed on total RNA
from mouse tissues and C2C12 cells cultured in normal and mitogen
poor medium using primers from 59 and 39 of striamin open reading
frame (ORF). Control RT-PCR was performed with glyceraldehyde-3-
phosphate dehydrogenase-specific primers.
Cellular Localization of striamin—The striamin ORF was ligated in
frame C-terminal to the GFP-ORF in pEGFPC1 vector (CLONTECH).
The plasmid encoding the GFP-striamin fusion protein was transfected
into COS7 cells growing on coverslips using LipofectAMINE™ (Life
Technologies, Inc.). Coverslips were incubated with nuclear dye,
Hoechst 33258 (Sigma) (5–10 mg/ml in culture medium for 10 min
before cell fixation), and fixed with methanol:acetone (1:1). After three
washings in phosphate-buffered saline, the coverslips were mounted
with Fluoromount (Difco). The cells were examined using an Olympus
BH-2 microscope with epifluorescence optics or 403 Plan-Neofluar ob-
jective on a Zeiss Axiophot microscope (Carl Zeiss, Germany) equipped
with a CELLscan system (Scanalytics, Billerica, MA). Microinjections of
the pGFPC1/striamin, pEGFPC1/N striamin (N-terminal 75 amino ac-
ids), or pEGFPC1/C striamin (C-terminal 74 amino acids) were per-
formed directly into the nuclei of NIH 3T3 cells growing on coverslips
using an Eppendorf semiautomated microinjection system mounted on
an inverted Zeiss microscope. Cells were fixed and examined for cellular
localization of striamin as described above.
p53-mediated Reporter Assays—p532/2 mouse embryonic fibro-
blasts were transfected with a p53-responsive luciferase reporter plas-
mid, PG-13luc (kindly provided by Dr. Bert Vogelstein). A temperature-
sensitive p53 expression plasmid, pMSVp53Val135 (a kind gift from Dr.
Paul Jackson) that results in wild-type p53 conformation at 32.5 °C was
used for exogenous p53 expression. Control expression plasmid pLK444
(15) or its striamin, N striamin (N-terminal 75 amino acids), or C
striamin (C-terminal 74 amino acids) containing derivatives, pLK444/
striamin, pLK444/N striamin, or pLK444/C striamin, respectively,
were cotransfected with the reporter plasmid. Cotransfections of pRL-
CMV were performed as an internal control to determine the efficiency
of transfections. Luciferase assays (Dual-LuciferaseTM reporter assay
system, Promega) were performed 48 h after transfection. Luciferase
values were calculated per microgram of protein as determined by
Bradford protein assay.
p532/2 mouse embryonic fibroblasts were microinjected with a mix-
ture of plasmids containing 0.1 mg/ml each of the pMSVp53Val135,
p53-responsive b-gal reporter pRGCDfos-lacZ (a kind gift from Dr.
David Wynford-Thomas), and pLK444 or pLK444/striamin. Control IgG
was co-injected for the identification of the injected cells. After over-
night incubation at 32.5 °C, the cells were fixed with 4% formaldehyde,
permeabilized with phosphate-buffered saline containing 0.1% Triton
X-100 for 5 min on ice, washed three times with phosphate-buffered
saline, and then stained with fluorescein isothiocyanate-conjugated
secondary antibodies to detect injected IgG and b-galactosidase expres-
sion using the b-gal staining kit (Roche Molecular Biochemicals). Cells
were viewed using a Zeiss microsope. All cells showing any trace of blue
staining were scored as positive for expression.
In Vivo Co-immunoprecipitations—COS7 cells were used for high
transfection efficiencies. Lysates (400 mg) prepared from pEGFPC1
vector-, pEGFPC1/striamin-, pEGFPC1/N striamin-, or pEGFPC1/C
striamin-transfected cells after 48 h of transfection were incubated with
anti-p53 antibody (CM-1, Novocastra Laboratories Ltd.) overnight at
4 °C. Immunocomplexes were precipitated by incubating with protein
A/G-Sepharose (30 min at 4 °C) and were analyzed for the presence of
striamin by Western blotting with anti-GFP monoclonal antibody. Pre-
cipitation of p53 was detected by Western blotting with anti-p53 mono-
clonal antibody (Ab-1, Calbiochem).
Preparation of Recombinant striamin Protein—The ORF of striamin
cDNA was amplified by PCR of pBSSK/striamin clone with sense (59-
GGA TCC AAG AAA GGC CTG GCT GGC GAG-39) and antisense
(59-AAG CTT TCA TGT CAC TGC CAC GCC TTC-39) primers with
BamHI and HindIII sites, respectively. The PCR-amplified 0.5-kb frag-
ment was first cloned in pGEM-T vector, confirmed to be correct by
DNA sequencing, excised with BamHI-HindIII, and then cloned into
pQE30 vector (Qiagen) to yield His-tagged protein. The pQE30/stri-
amin, pQE30/N striamin, and pQE30/C striamin constructs were used
to transform M15 bacteria, and cells grown to OD580 5 0.6 were induced
with isopropyl-1-thio-b-D-galactopyranoside (IPTG) (0.2 mM) at 37 °C
for 5 h. The bacterial lysates (induced and uninduced with IPTG) were
analyzed by SDS-polyacrylamide gel electrophoresis followed by West-
ern blotting with anti-His (Qiagen) and anti-p33 antibodies.
In Vitro Pull-down Assay—His-tagged recombinant striamin, N stri-
amin, and C striamin were purified from E. coli transformed with the
pQE30/striamin, pQE30/N striamin, and pQE30/C striamin construct,
respectively. Cells were centrifuged, and the pellets were resuspended
in buffer A (10 mM Tris-Cl, pH 7.5, 150 mM NaCl, 20 mM imidazole, 6 M
urea, and 5 mM b-mercaptoethanol), sonicated for 2 min on ice, and
agitated for 30 min at room temperature. The extract was centrifuged
at 15,000 3 g for 20 min. 0.5 ml of nickel-NTA-agarose affinity resin
(Qiagen) was added to the supernatant, and the mixture was agitated at
room temperature for 2 h. The mixture was then loaded into a dispos-
able plastic column, followed by washing with 20 ml of 10 mM Tris-Cl,
pH 7.5, and 0.5 M NaCl (TBS). The recombinant protein was eluted with
0.5 M imidazole in TBS followed by desalting on a PD-10 column (Am-
ersham Pharmacia Biotech) using TBS as eluent. Aliquots of the puri-
fied protein were stored at 220 °C until use. The purity of the prepa-
rations was examined by SDS-polyacrylamide gel electrophoresis and
Western analysis with anti-His antibody. Purified proteins (2–5 mg)
were incubated with GST or GST-p53 (1 mg, Santa Cruz) in an Nonidet
P-40-lysis buffer to a final volume of 500 ml. glutathione-Sepharose
beads (20 ml) were added after 2 h and rotated at 4 °C for 1 h. Beads
were pelleted by centrifugation, washed three times with TBS, boiled in
SDS sample buffer, and analyzed by Western blotting with anti-His tag
antibody.
Chromosomal Assignment—A mouse P1 genomic clone was obtained
by PCR screening of a P1 bacteriophage mouse genomic library with
clone 336-specific primers (sense: 59-TGGTATTCTTATATTGTTTG-
CAACTAACTA-39; antisense, 59-GGAAGGCCATGTGACCTAATGTT-
TCATGTCA-39). The isolated P1 clone was seen to hybridize with the
39-untranslated region of the gene, following which it was used for
chromosomal localization by fluorescence in situ hybridization (FISH).
DNA from the mouse P1 clone was labeled with digoxigenin-dUTP by
nick translation. Labeled probe was combined with sheared mouse
DNA and hybridized to metaphase chromosomes derived from mouse
embryonic fibroblasts in a solution containing 50% formamide, 10%
dextran sulfate, and 23 SSC. Specific hybridization signals were de-
tected by incubating the hybridized slides with fluoresceinated anti-
digoxigenin antibodies, followed by counterstaining with 49,69-
diamidino-2-phenylindole.
RESULTS
Cloning and Characterization of striamin cDNA—A compar-
ison of plasma membrane Triton X-100-insoluble fractions from
normal (CMEF) and immortal (NIH 3T3) murine cells revealed
a protein of nearly 33 kDa (called p33) present in NIH 3T3 but
not in CMEF cells (12). The protein was isolated from SDS-
polyacrylamide gels and was used for raising polyclonal anti-
body. The anti-p33 antibody thus raised was used for cDNA
cloning by immunoscreening of a RS-4 cDNA library as de-
scribed previously (16). Five cDNA clones were obtained and
were characterized by partial sequencing. Three clones showed
identity to known genes, namely FusCHOP, G-utrophin, and
dystrophin, while two clones had no matches in the DNA se-
quence data bases. The in vitro translated products of these two
novel clones could not be precipitated with the anti-p33 anti-
body, indicating that they were not related to the p33. The
characterization of one of these clones, 336, is described here.
The complete sequence of 336 (2.4 kb) contained one pre-
dicted ORF of 309 base pairs, which was located at the 59 end
of the cloned cDNA. 59 RACE PCR performed using skeletal
muscle cDNA generated an overlapping clone, 59 336. The
additional 59 sequence extended the ORF to 447 base pairs with
an upstream in-frame stop codon (Fig. 1). The full-length cDNA
sequence thus obtained had no homology to any sequence in the
DNA sequence data banks. Analysis of the cDNA sequence by
BLAST, PROSITE, GCG, and PSORT programs revealed no
known motifs that could predict its possible function. The 59-
noncoding sequence of striamin contains C/GAAAA repeats
and the 39-noncoding region contains GT repeats; however, the
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functional significance of these repeats is not known. It encodes
a 149-amino acid protein (pI 10.2) that also has no significant
matches in the protein data base. The ProtPram program pre-
dicted a soluble protein with average hydrophobicity of 0.5 and
aliphatic index of 0.74. Two protein kinase C phosphorylation
sites, SDR at 45–47 amino acid residues and SPK at 78–80
amino acid residues; one casein kinase II phosphorylation site,
SGLD at 12–15 amino acid residues; and two myristoylation
sites, GNYYCC at 111–116 and GTRWAK at 120–125 amino
acid residues, are predicted by the ScanProsite program. Other
interesting features of the protein include a high positive char-
ge; a large number of serine, leucine, and proline residues; and
the presence of four cysteines. The protein could not be char-
acterized as a member of any known gene family based upon
cDNA or protein sequence analyses. In view of its expression in
striated muscle (see below), the gene has been named striamin.
The predicted ORF was cloned in pBSSK, and in vitro trans-
lation was performed to confirm the existence of the ORF in the
given sequence. A protein of approximately 18 kDa mass was
detected (data not shown). The ORF was also cloned into the
bacterial expression vector pQE30, and recombinant protein
containing a 63His tag at the amino terminus was obtained.
The induction of the promoter by IPTG led to the synthesis of
a protein of approximately 18 kDa (data not shown).
Expression Analyses—Northern blotting of mouse and hu-
man tissues showed a strong reactivity of the striamin probe to
a 3.0-kb transcript in mouse and human skeletal muscle and
mouse heart (Fig. 2, A and B). It also reacted very weakly to
transcripts of approximately 4.0 and 8.0 kb from human and
4.0 kb from mouse tissues. We therefore performed RT-PCR on
mouse tissues and myoblasts with striamin primers (Fig. 2C).
An expected size of DNA fragment was obtained from heart and
myoblasts (Fig. 2C). This, together with the Northern data,
confirmed that the cloned cDNA corresponds to striamin that is
preferentially expressed in heart and skeletal muscle. We next
investigated whether striamin exhibits muscle fiber type spec-
ificity. Four fiber phenotypes, namely fast twitch fiber types
2A, 2B, and 2X and slow fiber type I, have been defined on the
basis of expression of the type of myosin heavy chain isoform
(17). striamin was predominantly expressed in fast (quadri-
ceps) versus slow fibers (soleus) (Fig. 3A). Northern analysis
using RNA isolated from mouse skeletal muscles of differing
fast and slow fiber content (quadriceps: 95% fast 2B, 4% fast 2X
(18); extensor digitorum longus: 60% fast 2B, 28% fast 2X, 12%
fast 2A (19); superficial gastrocnemius: 100% fast 2B (20);
diaphragm: 57% fast 2X, 34% fast 2A, 7% slow (20); and soleus:
45% fast 2A, 55% slow (21)) revealed that striamin is expressed
preferentially in fast glycolytic (2B) fibers (Fig. 3B).
We examined striamin expression during in vitro myogenesis
of C2C12 myoblasts. These cells were cultured in differentia-
tion medium, and RNA was isolated at various time points
representing gradual formation of myotubes as observed mi-
croscopically. Interestingly, a 4-day culture that showed about
80% myotube formation had negligible expression of striamin
as compared with the 1- and 2-day cultures, which had about
10–30% myotube formation (Fig. 3C). Consistent with this
Northern analysis, striamin RT-PCR from C2C12 cells cul-
tured in serum-supplemented and -deficient medium for 60–72
h exhibited its down-regulated expression in the latter (differ-
entiated myoblasts) (Fig. 2C, lanes 7 and 8).
Cellular Localization of striamin—COS7 cells were trans-
fected with a plasmid, pEGFPC1-striamin, encoding a GFP-
striamin fusion protein. Transfected cells had distinct green
fluorescence (Fig. 4A) in the nucleus that overlapped with the
nuclear dye, Hoechst 33258, staining (Fig. 4B). pEGFPC1-
striamin, pEGFPC1/N striamin (N-terminal 75 residues), and
pEGFPC1/C striamin (C-terminal 74 residues) were microin-
jected into the nucleus of NIH 3T3 cells. Whereas distinct green
nuclear fluorescence was detected for striamin as in the trans-
fection assays, N striamin and C striamin were both retained in
the cytoplasm (Fig. 4, a–c). Three dimensional image scanning
of cells revealed that the full striamin protein is localized in the
nucleus and is clearly excluded from nucleolar structures (Fig.
4a). N striamin was concentrated around the nuclear mem-
FIG. 1. Nucleotide and predicted
amino acid sequence of striamin. The
sequence obtained by 59 RACE PCR on
mouse skeletal muscle cDNA is under-
lined up to the 59 upstream in-frame stop
codon.
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brane (Fig. 4b), and C striamin in addition to its concentration
around the nucleus was also distributed diffusely in the cyto-
plasm (Fig. 4c). The present data and the fact that striamin
does not contain any known nuclear localization signal could
suggest that the predicted high positive charge of the native
protein may be responsible for its nuclear localization. Alter-
natively, striamin may translocate to the nucleus by interact-
ing with some nuclear localization signal-containing protein.
striamin Represses p53 Activity—Wild type (wt) p53 has a
role during cell differentiation (reviewed in Ref. 22). Evidence
in support of this includes the following: (i) overexpression of
exogenous wt p53 or endogenous wt p53 following cell irradia-
tion can partially restore differentiation of several tumor cells
(23, 24), (ii) up-regulation of p53 mRNA occurs during C2
differentiation (25), and (iii) interference with endogenous wt
p53 inhibits hematopoietic and muscle cell differentiation,
which is shown to be independent of its cell cycle activity (8). In
view of these reports and characteristics of striamin such as
nuclear localization and down-regulation with myogenic differ-
entiation, we asked whether striamin can interfere with p53
activity. p532/2 MEF cells were transfected with the wt p53-
responsive luciferase reporter plasmid (PG-13luc), a tempera-
ture-sensitive p53 expression plasmid, pMSVp53Val135, and
FIG. 2. Expression of striamin in
mouse and human tissues. A, mouse
multiple tissue Northern blot showing
striamin expression in skeletal muscle
and heart (shown by arrow). The probe
showed a weak reactivity to a transcript
of 4.0 kb in other tissues. B, human mul-
tiple tissue Northern blot showing stri-
amin expression in skeletal muscle
(shown by arrow). Probe reacted weakly
to transcripts of 8.0 and 4.0 kb in some
other tissues. RNA loading was assessed
by hybridization with an 18 S ribosomal
RNA oligonucleotide probe. C, striamin
RT-PCR was performed using total RNA
from mouse heart, kidney, testis, liver,
brain, spleen, and myoblasts cultured in
serum-supplemented and -deficient me-
dium (lanes 1–8, respectively). striamin
expression was detected in heart and
myoblasts, and was down-regulated with
differentiation (lanes 7 and 8).
FIG. 3. Expression in mouse skeletal muscle in vivo and in
vitro. A, Northern analysis for striamin expression in different muscle
fiber phenotypes. Expression was detected in fast (quadriceps) (lane 1)
and absent in slow (soleus) twitch fibers (lane 2). B, Northern analysis
for striamin on RNA from muscle fibers with varying composition of fast
and slow fibers. Lanes 1–5 contain RNA from quadriceps (95% fast 2B,
4% fast 2X), extensor digitorum longus (60% fast 2B, 28% fast 2X, 12%
fast 2A), superficial gastrocnemius (100% fast 2B), diaphragm (57% fast
2X, 34% fast 2A, 7% slow), and soleus (45% fast 2A, 55% slow). striamin
is expressed preferentially in fast glycolytic (2B) fibers. The blots were
hybridized with 18 S ribosomal RNA oligonucleotide probe for loading
controls. C, striamin expression in C2C12 cells undergoing differentia-
tion in vitro. Lane 1 has RNA from dividing myoblasts cultured in
normal growth medium, and lanes 2–5 have RNA from cells cultured in
differentiation medium for 24, 32, 40, and 88 h and showed approxi-
mately 10, 20, 30, and 85% myotube formation, respectively. Absence of
striamin is seen in the differentiated C2C12 culture (lane 5). Ethidium
bromide-stained gel with 28 S and 18 S RNA bands is shown as a
loading control.
FIG. 4. Intracellular localization of striamin. Transfection of
pEGFPC1-striamin resulted in distinct green fluorescence of GFP-stri-
amin fusion protein in the nuclei (A) of COS7 cells that overlapped with
Hoechst dye staining (B) shown by arrowheads. Microinjection of
pEGFPC1/striamin (a), pEGFPC1/N striamin (b) and pEGFPC1/C stri-
amin (c) plasmids into the nucleus of NIH 3T3 cells resulted in nuclear,
perinuclear, and cytoplasmic green fluorescence, respectively, as visu-
alized by laser scanning microscopy.
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either the pLK444 vector or pLK444/striamin. The presence of
the striamin expression construct caused a significant reduc-
tion in p53 reporter gene activity in four independent experi-
ments. This result demonstrated that striamin can inhibit the
transcriptional activity of p53 (Fig. 5A). Furthermore, cotrans-
fections of the antisense construct were seen to have a mild
positive effect on p53 activity (Fig. 5A). Similar results were
obtained following microinjection of pMSVp53Val135, the p53-
responsive b-gal reporter, pRGCDfos-lacZ and the various stri-
amin expression plasmids. Injected cells were identified by
coinjection of rabbit IgG that was visualized by staining with
fluorescein isothiocyanate-conjugated secondary antibody.
b-Gal staining was observed in 86% and 88% of cells injected
with control and antisense striamin plasmid, respectively, but
only in 5% of cells that were injected with striamin sense
construct (Fig. 5B). These data confirmed the repression of p53
activity by striamin and were consistent with its down-regula-
tion observed during C2C12 differentiation. To further charac-
terize the specificity of striamin-p53 interactions, we also per-
formed p53 reporter assays in which expression plasmids
encoding N-terminal 75 (N striamin) or C-terminal 74 (C stri-
amin) amino acid residues were transfected. Whereas full and
C striamin were seen to repress p53 activity, transfections of N
striamin were neutral (Fig. 5A).
In Vivo and in Vitro Interactions of striamin and p53—The
effect of striamin on the transcriptional activation function of
p53 prompted us to investigate a possible interaction between
these two proteins. We used COS7 cells for their high amounts
of wt p53 and high transfection efficiencies. p53 immunocom-
plexes from pEGFPC1- and pEGFPC1/striamin-transfected
cells when analyzed by Western blotting with anti-GFP anti-
body revealed the presence of GFP-striamin (Fig. 5C). This
demonstrated that the striamin interacts with p53 in vivo.
Similar immunoprecipitations were also performed from cells
expressing GFP-N striamin and GFP-C striamin fusion pro-
teins. The full, N-, and C- striamin were found to interact to
p53 (Fig. 5C); no coimmunoprecipitation of GFP tag was de-
tected in these experiments.
We next performed an in vitro pull-down assay for striamin
and p53. His-tagged recombinant striamin was incubated with
either GST alone (negative control) or with GST-p53. Western
analysis of glutathione-Sepharose-reacting complexes using an
anti-His tag antibody revealed the presence of His-tagged stri-
amin, demonstrating that striamin can physically interact with
p53 (Fig. 5D). Furthermore, as in the in vivo coimmunoprecipi-
tations, both N striamin and C striamin were found to bind to
p53 (Fig. 5D).
Chromosomal Localization—A mouse genomic P1 clone con-
taining the striamin gene was obtained by PCR screening of a
P1 library. In FISH analysis, this clone specifically hybridized
to a medium-sized chromosome, which appeared to be chromo-
some 12 on the basis of 49,69-diamidino-2-phenylindole stain-
ing. To confirm the localization of striamin to mouse chromo-
some 12, FISH analysis was repeated using the P1 clone and
chromosome 12 centromere-specific probe. The striamin P1 and
chromosome 12 probes localized to the same chromosome (Fig.
Fig. 5. Interaction of striamin and p53. A, effect of striamin on transcriptional activity of wild type p53. p53-expression (pMSVp53Val135) and
p53-responsive luciferase reporter (PG-13luc) plasmids were transfected into p532/2 mouse embryonic fibroblasts (MEF) along with antisense
(AS) or sense (S) expression constructs encoding full, N-terminal 75 (N striamin), and C-terminal 74 (C striamin) amino acid residues. Numbers
indicate the amount (ml) of each plasmid (0.5 mg/ml) used. Error bars represent standard deviation (n 5 3). A 4.6-fold repression of p53 activity was
observed with cotransfection of the full striamin sense construct, whereas the antisense construct resulted in 1.6-fold activation. Co-transfections
of C striamin resulted in repression of p53 activity similar to the full striamin protein. N striamin was neutral. B, repression of p53 activity by
microinjected striamin. p532/2 cells were microinjected with p53-expression (pMSVp53Val135) and p53-responsive b–gal reporter (pRGCDfos-
lacZ) plasmids with or without striamin sense or antisense expression constructs. Injected cells were visualized by staining with fluorescein
isothiocyanate-conjugated anti-rabbit IgG (upper panel) and are shown by arrows in the lower panel. Blue staining for b-gal expression was
observed in cells coinjected with vector (a and d) and the antisense construct (c and f). Coinjection of striamin (b and e) resulted in repression of
p53 activity as demonstrated by the absence of b-gal staining (e). Note: dense blue stain in some cells caused interference in visualization of
fluorescein isothiocyanate staining (e and f). C, in vivo coimmunoprecipitation of striamin and p53. p53 immunocomplexes from COS7 cells
transfected with GFP vector or the one encoding GFP-full striamin, GFP-N striamin, or GFP-C striamin fusion protein were analyzed by Western
blotting with anti-GFP antibody. Protein fractions of the cell lysates that were soluble in Nonidet P-40 lysis buffer and the remaining that were
solubilized by boiling in 0.5% SDS were used for immunoprecipitaion. GFP-full striamin, -N striamin, or -C striamin were found to coprecipitate
with p53 (right panel); no coprecipitation was observed with control antibody (middle panel) or of the GFP tag only with anti-p53 antibody (right
panel, lanes 1 and 5). Input (left panel) shows 10% of the protein used for immunoprecipitation. Co-immunoprecipitated p53 was detected by
Western blotting with anti-p53 antibody (Ab-1, upper right panel). D, in vitro coimmunoprecipitation of striamin and p53. His-tagged recombinant
full striamin, N-striamin or C-striamin (5% of the input; lanes 1–3) were mixed with GST (lanes 4–6) or GST-p53 (lanes 7–9) and were precipitated
by glutathione-Sepharose beads. GST-Complexes were analyzed by Western blotting with anti-p53 (CM-1) and anti-His tag antibody. The full
striamin, N striamin, and C striamin were seen to coprecipitate with p53 (lanes 7–9).
FIG. 6. A, chromosomal localization of
striamin on mouse metaphase chromo-
somes. striamin and chromosome 12-spe-
cific probes are seen as green fluores-
cence, and are also marked by triangles
and arrows, respectively. B, diagram-
matic representation of striamin on
mouse chromosome 12C3 region.
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6). A total of 80 metaphase cells were analyzed, out of which 71
exhibited specific labeling. Measurements of specifically hy-
bridized chromosome 12 in 10 metaphase spreads demon-
strated that striamin is located at a position that is 57% of the
distance from the heterochromatic-euchromatic boundary to
the telomere of chromosome 12, an area that corresponds to
band 12C3. This region is syntenic to human chromosome
14q21–22.
DISCUSSION
Here we report cloning and characterization of a novel gene,
striamin, whose expression is restricted to the striated mus-
cles. The expression pattern of striamin shares features in
common with a few other genes, but is most similar to that of
MyoD. Both are expressed in proliferating myoblasts, decline
during differentiation, and yet are present in adult skeletal
muscle (26). Furthermore, they appear to be preferentially
expressed in fast glycolytic muscle fibers in the adult mouse
(27). In adult myofibers myoD is thought to mediate innerva-
tion and thyroid hormone effects on fiber type-specific gene
expression (26) as well as repress slow isoform gene function
(28). Other genes that are specific to fast glycolytic fiber include
myosin heavy chain 2B (MyHC 2B) (reviewed in Ref. 29) and a
muscle-specific form of the glycolytic enzyme aldolase A (M-
aldA) (30). Therefore, striamin may function as a mediator of
extrinsic factors on gene expression in fast glycolytic fibers, as
a determinant of metabolism, or as a determinant of muscle
contractile activity.
Adult skeletal muscle can undergo regeneration, repair, and
growth in response to injury or various stresses (31, 32). These
processes are achieved by the activation of muscle precursor or
satellite cells. In normal skeletal muscle, satellite cells are
mitotically quiescent, mononucleated cells that are situated
between the basement membrane and the myofiber plasma
membrane. Injury or stress results in the mitotic activation of
the satellite cells, which proliferate and fuse to repair damaged
fibers or increase the size of existing fibers. The progression
from proliferating to fusion competent satellite cells is marked
by a precise order of expression of myogenic regulatory factors
and muscle structural proteins. This includes, in order, MyoD,
myogenin, a-smooth muscle actin, and sarcomeric myosin (33).
Because striamin is expressed in myoblasts in culture, it is a
candidate marker for activated satellite cells and may play a
role in the differentiation process in vivo.
striamin is expressed in mouse, but not in human, heart.
Differences exist between rodent and human cardiac myofibers
in contraction velocities and force production, which in large
part reflects the ATPase activity conferred by the MyHC iso-
form present (34). a-MyHC, the predominant isoform in the
rodent heart, confers a faster shortening velocity and low effi-
ciency of force production. In contrast, b-MyHC predominates
in the human heart, which has a slower shortening velocity and
high efficiency of force production. Rodent and human hearts
also differ in the relative amounts of sarcomeric actins present,
cardiac and skeletal actin (35, 36), which most likely reflects a
difference in force development (37). The combinations of
MyHCs and sarcomeric actins in rodent versus human heart
results in a rodent heart that is more similar in contractile
properties to a fast-twitch skeletal muscle fiber, whereas the
opposite is true for the human heart. Therefore, the expression
of striamin in striated muscles and mouse heart is consistent
with a role in a fast contractile phenotype.
striamin Was Found to Interact with p53 in Vitro and in
Vivo—Repression of p53 activity by striamin is consistent with
its down-regulation during in vitro myogenesis when signifi-
cant increase in p53 activity has been reported (22). These data
suggests that striamin may affect myogenesis via a direct in-
teraction with p53. Our data suggested that both the N- and
C-terminal halves of striamin protein can bind to p53; however,
it is the C terminus of striamin that represses transcriptional
activity of p53. This suggests that there are more than one p53
binding sites in striamin protein and vice versa. Characteriza-
tion of these warrant further studies.
The myogenic differentiation program includes activation of
myogenic transcription factors, intercellular fusion of myo-
blasts, their withdrawal from the cell cycle, and terminal dif-
ferentiation to myotubes. Besides the muscle-specific family of
transcription factors, myoD family, several adhesion molecules
such as N-CAM, N-cadherin, very late activation antigen 4,
vascular cell adhesion molecule 1 (VCAM-1), and meltrin-a
have been implicated in this process (38–41). Bone morphoge-
netic protein-12 and -13, TGF-b, and other members of the
TGF-b superfamily (42, 43), ERK-6, a mitogen-activated pro-
tein kinase (44), and PAX3 (45) have been shown to interfere
with or suppress in vitro myogenesis of C2C12 myoblasts.
Cyclin D1 is found to be down regulated with myogenesis of
C2C12, in contrast to cyclin D2, which showed transient in-
crease, and cyclin D3, which showed 20-fold increase (7, 46).
striamin does not show any structural homology to any of these
proteins that have been implicated in different aspects of mus-
cle differentiation. Of particular interest are its fast fiber spec-
ificity, nuclear localization, down-regulation with myogenic dif-
ferentiation, and functional interactions with the tumor
suppressor p53, which may predict it to be an important gene
in the regulation of the myogenic differentiation program and
warrant further studies to elucidate its role in myogenesis and
the fast contractile phenotype.
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